Unigene Laboratories, Inc. - Product Pipeline Review - Q1 2011

Global Markets Direct, June 2011, Pages: 40

Unigene Laboratories, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Unigene Laboratories, Inc. - Product Pipeline Review - Q1 2011” provides data on the Unigene Laboratories, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Unigene Laboratories, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Unigene Laboratories, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Unigene Laboratories, Inc. - Brief Unigene Laboratories, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Unigene Laboratories, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Unigene Laboratories, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Unigene Laboratories, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Unigene Laboratories, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Unigene Laboratories, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Unigene Laboratories, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Unigene Laboratories, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Unigene Laboratories, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Unigene Laboratories, Inc. Snapshot
Unigene Laboratories, Inc. Overview
Key Information
Key Facts
Unigene Laboratories, Inc. – Research and Development Overview
Key Therapeutic Areas
Unigene Laboratories, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Unigene Laboratories, Inc. – Pipeline Products Glance
Unigene Laboratories, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Unigene Laboratories, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Unigene Laboratories, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Unigene Laboratories, Inc. – Drug Profiles
sCT nasal
Product Description
Mechanism of Action
R&D Progress
sCT oral
Product Description
Mechanism of Action
R&D Progress
PTH Analogs Oral
Product Description
Mechanism of Action
R&D Progress
Annexin Analogs
Product Description
Mechanism of Action
R&D Progress
CGRP
Product Description
Mechanism of Action
R&D Progress
Desmopressin
Product Description
Mechanism of Action
R&D Progress
GLP-1 analogs oral
Product Description
Mechanism of Action
R&D Progress
sCT-GC Combination Therapy
Product Description
Mechanism of Action
R&D Progress
UGP281
Product Description
Mechanism of Action
R&D Progress
Unigene Laboratories, Inc. – Pipeline Analysis
Unigene Laboratories, Inc. – Pipeline Products by Therapeutic Class
Unigene Laboratories, Inc. - Pipeline Products By Target
Unigene Laboratories, Inc. – Pipeline Products by Route of Administration
Unigene Laboratories, Inc. – Pipeline Products by Molecule Type
Unigene Laboratories, Inc. – Recent Pipeline Updates
Unigene Laboratories, Inc. - Dormant Projects
Unigene Laboratories, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Unigene Laboratories, Inc., Deals Volume Summary, 2004 to YTD 2011
Unigene Laboratories, Inc., Deals Summary By Region, 2004 to YTD 2011
Unigene Laboratories, Inc., Deals Summary, 2004 to YTD 2011
Unigene Laboratories, Inc. Detailed Deal Summary
Equity Offering
Unigene Laboratories Withdraws Public Offering Of $30 Million
Debt Offering
Unigene Laboratories Completes Private Placement Of Secured Non-Convertible Senior Notes For $5 Million
Licensing Agreements
Unigene Laboratories Enters Into Licensing Agreement With Tarsa Therapeutics
Unigene Laboratories Enters Into Licensing Agreement With Novartis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Unigene Laboratories, Inc. – Pipeline by Therapy Area and Indication, 2011
Unigene Laboratories, Inc. – Pipeline by Stage of Development, 2011
Unigene Laboratories, Inc. – Monotherapy Products in Pipeline, 2011
Unigene Laboratories, Inc. – Phase III, 2011
Unigene Laboratories, Inc. - Phase II, 2011
Unigene Laboratories, Inc. - Pipeline By Therapeutic Class, 2011
Unigene Laboratories, Inc. - Pipeline By Target, 2011
Unigene Laboratories, Inc. – Pipeline By Route of Administration, 2011
Unigene Laboratories, Inc. – Pipeline By Molecule Type, 2011
Unigene Laboratories, Inc. – Recent Pipeline Updates, 2011
Unigene Laboratories, Inc. - Dormant Developmental Projects, 2010
Unigene Laboratories, Inc., Other Locations
Unigene Laboratories, Inc., Deals Summary, 2004 to YTD 2011
Unigene Laboratories, Inc., Deals Summary by Region, 2004 to YTD 2011
Unigene Laboratories, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
Unigene Laboratories, Inc. – Pipeline by Therapy Area and Indication, 2011
Unigene Laboratories, Inc. – Pipeline by Stage of Development, 2011
Unigene Laboratories, Inc. – Monotherapy Products in Pipeline, 2011
Unigene Laboratories, Inc. – Pipeline By Therapeutic Class, 2011
Unigene Laboratories, Inc. - Pipeline By Target, 2011
Unigene Laboratories, Inc. – Pipeline By Route of Administration, 2011
Unigene Laboratories, Inc. – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Abbott Laboratories - IT Sales Opportunities - 2009
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Accenture - Profile - US